Sugi Predict

Sugi Predict / Compounds / SCHEMBL19915501

SCHEMBL19915501

SCHEMBL19915501

CC(C)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)Nc1ccc(COC(=O)C(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MMP3 P08254 1/20 0.41
▸ ROCK2 O75116 1/20 0.39
▸ PRSS1 P07477 4/20 0.37
▸ TPSAB1 Q15661 2/20 0.37
▸ PLG P00747 1/20 0.37
▸ F2 P00734 3/20 0.36
▸ PRSS2 P07478 3/20 0.36
▸ PRSS3 P35030 3/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ KDM1A O60341 3/20 0.35
▸ MAOA P21397 2/20 0.35
▸ KDM1B Q8NB78 1/20 0.35
▸ RCOR1 Q9UKL0 1/20 0.35
▸ MME P08473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13775167 0.88 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2ROCK2PRSS1
SCHEMBL24859437 0.86 MMP3 (0.42) NPC1RAB9ASMN1; SMN2MMP3ROCK2
SCHEMBL17302707 0.83 LTA4H (0.44) NPC1RAB9ASMN1; SMN2MMP3PRSS1
SCHEMBL19915499 0.83 ROCK2 (0.45) NPC1RAB9ASMN1; SMN2ROCK2TPSAB1
SCHEMBL25854487 0.82 LTA4H (0.43) NPC1RAB9ASMN1; SMN2MMP3PRSS1
SCHEMBL23190207 0.81 MMP3 (0.36) NPC1RAB9ASMN1; SMN2MMP3ROCK2
SCHEMBL24479489 0.80 RAB9A (0.41) NPC1RAB9ASMN1; SMN2MMP3PRSS1
SCHEMBL24471650 0.80 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2MMP3ROCK2
SCHEMBL25854480 0.79 HDAC2 (0.39) NPC1RAB9ASMN1; SMN2MMP3PRSS1
SCHEMBL25863220 0.79 HDAC2 (0.39) NPC1RAB9ASMN1; SMN2MMP3PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10772965-B2 Covalent linkers in antibody-drug conjugates and methods of making and using the same RC BIOTECHNOLOGIES, INC. (US) 2020-09-15 — — US disclosed
US-20180169250-A1 COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME REMEGEN CO., LTD. (CN) 2018-06-21 — — US disclosed
US-20180055948-A1 Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same REMEGEN CO., LTD. (CN) 2018-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169250-A1 COVALENT LINKERS IN ANTIBODY-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME DHFR, FCGR1A, ADCY4 NPC1 4243/4885RAB9A 2196/4885SMN1; SMN2 3762/4885
US-20180055948-A1 Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same DHFR, FCGR1A, ADCY4 NPC1 4243/4885RAB9A 2196/4885SMN1; SMN2 3762/4885
US-10772965-B2 Covalent linkers in antibody-drug conjugates and methods of making and using the same DHFR, FCGR1A, ADCY4 NPC1 4243/4885RAB9A 2196/4885SMN1; SMN2 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.